Pricing Log in Create free account

AIM ImmunoTech Inc. (AIM) vs Orgenesis Inc. (ORGS)

AIM ImmunoTech Inc. and Orgenesis Inc. are both Biotechnology companies. AIM ImmunoTech Inc. and Orgenesis Inc. are of similar size ($6.1M and $5.7M). Orgenesis Inc. grew revenue faster over the last twelve months: 95.3% against −21.5%. Orgenesis Inc. has the higher net margin (−4,653.6% vs −15,021.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, AIM ImmunoTech Inc. leads on 8 and Orgenesis Inc. on 8.

Valuation

Metric AIM ORGS Biotechnology median
P/E n/m n/m 10.60
P/S 28.83 1.42 9.40
P/B 0.35 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.70 n/m 0.66
EV/Sales (71.38) 16.89 9.02
Earnings yield (2,575.37%) (3,288.57%) (32.88%)
Free cash flow yield (533.84%) (1,176.50%) (23.13%)

Profitability

Metric AIM ORGS Biotechnology median
Gross margin (23.16%) (86.28%) 68.51%
Operating margin (11,724.21%) (3,842.32%) 0.00%
Net margin (15,021.05%) (4,653.62%) 0.00%
Free cash flow margin (15,385.26%) (1,675.27%) 0.00%
Return on equity (2,382.30%) 164.62% (51.96%)
Return on assets (169.28%) (605.73%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AIM ORGS Biotechnology median
Revenue growth (TTM) (21.49%) 95.28% 6.76%
EPS growth (last fiscal year) 72.19% 40.10% 29.88%
Revenue growth, 5-year CAGR (11.60%) (23.30%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AIM ORGS Biotechnology median
Debt to equity 0.00 (0.44) 0.00
Current ratio 2.11 0.03 4.97
Net debt to EBITDA 0.22 (0.42) 1.01

Dividend

Metric AIM ORGS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AIM ORGS Biotechnology median
Market cap 6.07m 5.68m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack